Takeda acquires PvP Biologics
The acquisition follows the conclusion of a Phase I proof-of-mechanism study of investigational medicine TAK-062.
Read More
Author: Anna Smith
Polivy struck by NICE ‘no’
NICE is citing “substantial uncertainty in the submitted data” as a reason not to recommend the drug, as well as a lack of “strong long-term evidence on remission with the treatment.”
Read More
AZ divests Movantik rights to RedHill
The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.
Read More
EMA, FDA both accept filing of Novartis’ ofatumumab
In two head-to-head studies, ofatumumab demonstrated superiority over Aubagio in patients with relapsing forms of multiple sclerosis.
Read More
‘Smart watches’ for Alzheimer’s discussed as numbers set to double by 2050
Alzheimer’s is a complex disease and one of the largest challenges facing healthcare today, with lots of failed treatments in past pipelines.
Read More- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
